Andrei Stefan, Iorgoveanu Corina
CNHO des Quinze-Vingts, Service de Médecine Interne, Paris, France.
CC Iliescu Institute of Cardiovascular Diseases, Cardiology, Bucharest, Romania.
Discoveries (Craiova). 2014 Dec 31;2(4):e33. doi: 10.15190/d.2014.25.
Heart failure is a worldwide leading cause of hospital admissions. There is a critical need for new methods of management in acute heart failure. The current drug panel available in the treatment of hemodinamically unstable patients is not only limited, but it is also associated with deleterious side effects. Discoveries in the heart failure field seemed to lack an adequate answer and a change in paradigm may be necessary. The cardiac myosin activator omecamtiv mecarbil is a new therapeutic approach that improves the myocardial contractility through an innovative mechanism, avoiding the harmful effects of currently used inotropic agents. Several studies provided us with promising results, but further scientific proofs are needed.
心力衰竭是全球范围内导致住院的主要原因。急性心力衰竭迫切需要新的管理方法。目前用于治疗血流动力学不稳定患者的药物种类不仅有限，而且还伴有有害的副作用。心力衰竭领域的研究似乎缺乏充分的答案，可能需要转变范式。心肌肌球蛋白激活剂omecamtiv mecarbil是一种新的治疗方法，它通过创新机制改善心肌收缩力，避免了目前使用的强心剂的有害作用。多项研究为我们提供了有希望的结果，但还需要进一步的科学证据。
